^

About Us

VERI is a data platform to link predictive biomarkers in oncology and drug response.


The database was created by a global team of expert analysts at LARVOL VERI, a technology company with 15 years of experience in data curation for the pharmaceutical and biotechnology industry.


The goal of VERI is to become the most broad and relied upon tool for physicians, researchers and industry leaders who are involved in precision medicine.


By using this database, you are agreeing to our

Terms of Services
and
Privacy Policy.


VERI covers broad array of genetic alterations, types of markers, expression changes, complex phenotypes.

Genes

4213

Biomarkers

6312

Cancers

159

Drugs

5711

Drug classes

850

Tests

771

Companies

315

VERI aims to cover the full development cycle capturing data ranging from preclinical to guidelines to regulatory approvals.

A1 Approval

1828

A2 Guideline

3623

B Late Trial

3339

C Early Trial

29205

D Preclinical

5827